ADVERTISEMENT
Real-world data: Different administration strategies of fruquintinib for metastatic colorectal cancer
Background
Targeted therapy is currently the third-line standard treatment for advanced colorectal cancer. In actual clinical practice, there are many experts who choose the strategy of combining targeted therapy with immunotherapy. As one of the third-line targeted therapeutic drugs, fruquintinib has three common applications: 1. fruquintinib monotherapy (Monotherapy); 2. fruquintinib combined with immunotherapy (Combined); 3.fruquintinib monotherapy sequenced by fruquintinib combined with immunotherapy (Sequential). Therefore, our study mainly explored the influence of different administration strategies on the survival time of patients.
Methods
This was a retrospective study in patients with advanced colorectal cancer performed from February 1, 2020 to March 10, 2022. According to the wishes of patients and the choice of clinicians, patients received different fruquintinib-based regimens. The primary end point was progression free survival (PFS).
Results
A total of 71 patients were eligible for response assessment. In the general population, complete response (CR) was not observed, 2 patients achieved partial response (PR), 45 patients had stable disease (SD) and 24 patients had progression disease (PD). The ORR and DCR were 2(3%) and 47(66%), respectively. The median PFS of all populations was 6.4 months. The PFS of monotherapy group was 5.3 months. The PFS of combined group was 6.4 months. And the PFS of sequential group was 12.8 months. However, perhaps due to the small sample size, the difference between the three groups was not statistically significant (p=0.178).
Conclusions
In the third and later lines of treatment for advanced colorectal disease, where there is a trend toward slow disease progression during fruquintinib monotherapy, many clinicians choose to combine targeted therapy with immunotherapy to further prolong patient survival. Our real-world data suggest that a sequential treatment approach is a very promising therapeutic strategy, but more clinical data are needed to further validate our conclusions.
Legal entity responsible for the study
The author.
Funding
This work was financially supported by the Science and Technique Foundation of Henan Province (No. 202102310121 for J.-Z. W), the Medical Science and Technology Co-construction Project of Henan Province (No. LHGJ20200167), the 1000 Talents Program of Central plains (No. 204200510023 for X.-B. C), and the Sate Key Laboratory of Esophageal Cancer Prevention & Treatment (No. Z2020000X for X.-B. C).
Disclosures
All authors have declared no conflicts of interest.
